On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
Portfolio Pulse from Benzinga Newsdesk
Paragon Therapeutics has announced a license agreement with Spyre Therapeutics, granting Spyre exclusive rights to certain antibodies and products targeting α4ß7 integrin and TL1A. Paragon will receive up to $22 million in milestone payments and royalties from Spyre.
May 15, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spyre Therapeutics has secured an exclusive license from Paragon Therapeutics for antibodies targeting α4ß7 integrin and TL1A, with potential milestone payments up to $22 million and royalties.
The exclusive license agreement with Paragon Therapeutics is a significant development for Spyre Therapeutics, potentially leading to new product offerings and revenue streams. The milestone payments and royalties indicate a positive financial impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100